Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2019 to Jul 2024
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs to
treat diseases of aging such as Type 2 Diabetes, announced today that a
member of its Scientific Advisory Board and two of its scientists will
be presenting at the Keystone Symposia’s Diabetes
Mellitus, Insulin Action and Resistance Conference in Breckenridge,
Colorado January 22-27. The presentations will include data on the
impact of a new chemical activator of SIRT1, an enzyme shown to increase
insulin sensitivity and improve glucose levels when stimulated in
pre-clinical models of Type 2 Diabetes.
Johan Auwerx, MD, PhD, a member of Sirtris’
Scientific Advisory Board and Professor at the Medical Faculty of the
University of Strasburg and Co-director of the Mouse Clinical Institute
(ICS) in Strasburg, France, will speak during the session on New
Molecular Mechanisms of Insulin Resistance. His talk will be on
Saturday, January 26 from 8-11:30 am CST. Professor Auwerx will present
new data that includes the impact of one of Sirtris’
new chemical entities (NCEs) in mice on a high-fat diet.
Heidi Galonek, PhD of Sirtris Pharmaceuticals will present her poster
titled Small Molecule Activators of SIRT1 Suppress Inflammatory
Signaling Pathways In Vivo on Wednesday, January 23 from 7:30-10:00
pm CST. “This work, which also used one of
Sirtris’ new chemical entities, suggests SIRT1
activators could address the chronic low grade inflammation associated
with Type 2 Diabetes,” said Michael Jirousek,
PhD, Senior Vice President of Research. “In
addition, we demonstrated that we could improve insulin sensitivity and
glucose homeostatsis.”
Jesse Smith, PhD, also of Sirtris Pharmaceuticals, will present his
poster titled Small Molecule Activators of SIRT1 Mimic Calorie
Restriction In Vivo: A Novel Therapeutic Strategy in Treating
Type II Diabetes on Friday, January 25 from 7:30-10:00 pm CST. “This
work demonstrates that small molecules can mimic aspects of calorie
restriction (CR) and provides further understanding of the mechanisms at
work,” said Jirousek. “In
a blinded analysis, databases at a computational systems biology company
concluded that the strongest hypothesis for the results seen in our
study was calorie restriction—showing that
our novel SIRT1 activators are mimicking the effects of calorie
restriction.”
"Sirtris is dedicated to building a broad platform of sirtuin
therapeutics for diseases of aging,” said
Sirtris Chief Executive Officer and Vice Chair Christoph Westphal, MD,
PhD. “Our research program is continuously
progressing new chemical entities toward the clinic with the first NCE
planned to enter human trials in the first half of 2008."
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small molecule
drugs with the potential to treat diseases associated with aging,
including metabolic diseases such as Type 2 Diabetes. Our drug
candidates are designed to mimic certain beneficial health effects of
calorie restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes that
control the aging process. The company's headquarters are in Cambridge,
Massachusetts.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
statements include, but are not limited to, the potential therapeutic
effects of SIRT1 activators for diseases of aging, such as Type 2
Diabetes; the progress and results of pre-clinical studies of new
chemical entities and pre-clinical and clinical studies of SIRT1
activators; development of first-in-class therapeutics known as new
chemical entities that modulate sirtuins; and the potential of sirtuin
modulators to receive regulatory approval. These forward-looking
statements about future expectations, plans and prospects of Sirtris
Pharmaceuticals involve significant risks, uncertainties and
assumptions, including risks related to the lack of results that would
provide a basis for predicting whether any of the Company's product
candidates will be safe or effective, or receive regulatory approval,
the possibility that results of pre-clinical studies are not necessarily
predictive of clinical trial results, the Company's potential inability
to initiate and complete pre-clinical studies and clinical trials for
its product candidates, the fact that none of the Company's product
candidates has received regulatory approvals, the potential inability of
the Company to gain market acceptance of the Company's product
candidates, and those other risks factors that can be found in the
Company's filings with the Securities and Exchange Commission. Actual
results may differ materially from those Sirtris Pharmaceuticals
contemplated by these forward-looking statements. Sirtris
Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or events or
circumstances that occur after the date of this release.